Matching donors and recipients for better outcomes
With a new investment of nearly $6 million, A national prospective epitope-compatibility matching program for Canadian renal transplant patients has outlined a world-first epitope based program that aims to reduce patients’ risk of organ rejection, minimize toxic immune suppression, and eliminate the need for lifelong immunosuppressive therapy.
Led by Paul Keown from the University of British Columbia (UBC), this project partners with Canadian Blood Services to fulfill this visionary genomics-based solution for better matching donors and recipients for kidney transplants.
The project will be tested in BC and builds on decades of previous Genome Canada-funded work. It was part of a larger $41 million investment made in May 2024.
ABOUT GAPP
The Genomic Applications Partnership Program (GAPP) supports industry-facing partnered research projects that address real-world challenges. Designed to accelerate the social and economic impact of genomics, GAPP provides the space for research, innovation and application to thrive collaboratively. GAPP projects address real-world challenges and opportunities through greater collaboration between genomics scientists and the users of genomics research. They aim to stimulate public- and private-sector investment in Canadian genomics technologies, advancing technology uptake in receptors and moving technologies across readiness levels.